{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:23:33Z","timestamp":1784661813911,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The carbonic anhydrase (CA) enzyme plays an important role in the equilibration of carbon dioxide and bicarbonate (HCO\n                      <jats:sub>3<\/jats:sub>\n                      ) under the production of H\n                      <jats:sup>+<\/jats:sup>\n                      ions. Emerging evidence suggest that CA activity may play a fundamental regulatory role on respiratory control mechanisms in obstructive sleep apnea (OSA). Clinical trials suggest that CA inhibitors significantly reduce OSA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from three separate cohorts of healthy volunteers and patients with OSA were used to quantify CA activity in whole blood and cerebrospinal fluid (CSF). The influence of the CA inhibitory drugs acetazolamide and sulthiame, on CA activity in-vitro\/in-vivo, was assessed. The association between CA-inhibitor plasma concentration and HCO\n                      <jats:sub>3<\/jats:sub>\n                      , as well as the influence of HCO\n                      <jats:sub>3<\/jats:sub>\n                      on the apnea-hypopnea severity was determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Stability of CA activity in stored blood was high. CA activity in whole blood contained five times higher activity compared with CSF. The CA-inhibitory drugs dose-dependently reduced CA activity in-vitro\/in-vivo. The CA inhibitor sulthiame reduced venous HCO\n                      <jats:sub>3<\/jats:sub>\n                      concentration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022). The reduction of HCO\n                      <jats:sub>3<\/jats:sub>\n                      was linked to improvement of OSA (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.040).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CA-inhibitory drugs reduced CA activity in whole blood suggesting a therapeutic role of CA inhibition in OSA. The findings also suggest that an activated CA system may constitute a pathophysiological mechanism in some forms of OSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11325-025-03430-z","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:49:14Z","timestamp":1756968554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduction of carbonic anhydrase activity is associated with amelioration of obstructive sleep apnea"],"prefix":"10.1007","volume":"29","author":[{"given":"Ali M.","family":"Komai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Musovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Stenl\u00f6f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Grote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-394X","authenticated-orcid":false,"given":"Jan","family":"Hedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"4","key":"3430_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","volume":"47","author":"TH Maren","year":"1967","unstructured":"Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and Inhibition. Physiol Rev 47(4):595\u2013781","journal-title":"Physiol Rev"},{"issue":"7","key":"3430_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.5665\/sleep.4814","volume":"38","author":"T Wang","year":"2015","unstructured":"Wang T, Eskandari D, Zou D, Grote L, Hedner J (2015) Increased carbonic anhydrase activity is associated with sleep apnea severity and related hypoxemia. Sleep 38(7):1067\u20131073","journal-title":"Sleep"},{"issue":"3","key":"3430_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.chest.2023.09.022","volume":"165","author":"E Hoff","year":"2024","unstructured":"Hoff E, Strassberger C, Zou D, Grote L, Stenlof K, Hedner J (2024) Modification of endotypic traits in OSA by the carbonic anhydrase inhibitor sulthiame. Chest 165(3):704\u2013715","journal-title":"Chest"},{"issue":"7","key":"3430_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/138161208783877884","volume":"14","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases\u2013an overview. Curr Pharm Des 14(7):603\u2013614","journal-title":"Curr Pharm Des"},{"issue":"6","key":"3430_CR5","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/med.21713","volume":"40","author":"CB Mishra","year":"2020","unstructured":"Mishra CB, Tiwari M, Supuran CT (2020) Progress in the development of human carbonic anhydrase inhibitors and their Pharmacological applications: where are we today? Med Res Rev 40(6):2485\u20132565","journal-title":"Med Res Rev"},{"issue":"12","key":"3430_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","volume":"27","author":"CT Supuran","year":"2018","unstructured":"Supuran CT (2018) Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 27(12):963\u2013970","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"3430_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L et al (2020) A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 43(7):484\u2013490","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"3430_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/14737175.2016.1193009","volume":"16","author":"CT Supuran","year":"2016","unstructured":"Supuran CT (2016) Carbonic anhydrase Inhibition and the management of neuropathic pain. Expert Rev Neurother 16(8):961\u2013968","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"3430_CR9","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1164\/rccm.202109-2043OC","volume":"205","author":"J Hedner","year":"2022","unstructured":"Hedner J, Stenlof K, Zou D, Hoff E, Hansen C, Kuhn K et al (2022) A randomized controlled clinical trial exploring safety and tolerability of sulthiame in sleep apnea. Am J Respir Crit Care Med 205(12):1461\u20131469","journal-title":"Am J Respir Crit Care Med"},{"key":"3430_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.sleep.2023.04.010","volume":"107","author":"YN Ni","year":"2023","unstructured":"Ni YN, Holzer RC, Thomas RJ (2023) Acute and long-term effects of Acetazolamide in presumed high loop gain sleep apnea. Sleep Med 107:137\u2013148","journal-title":"Sleep Med"},{"issue":"4","key":"3430_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","volume":"34","author":"SE Mohammadianinejad","year":"2011","unstructured":"Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R et al (2011) Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 34(4):174\u2013177","journal-title":"Clin Neuropharmacol"},{"issue":"16","key":"3430_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2014.3312","volume":"311","author":"NIIHSGW Committee","year":"2014","unstructured":"Committee NIIHSGW, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE et al (2014) Effect of Acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 311(16):1641\u20131651","journal-title":"JAMA"},{"issue":"4","key":"3430_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2018.206094","volume":"104","author":"L Vaclavu","year":"2019","unstructured":"Vaclavu L, Meynart BN, Mutsaerts H, Petersen ET, Majoie C, VanBavel ET et al (2019) Hemodynamic provocation with Acetazolamide shows impaired cerebrovascular reserve in adults with sickle cell disease. Haematologica 104(4):690\u2013699","journal-title":"Haematologica"},{"issue":"1","key":"3430_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12931-017-0607-9","volume":"18","author":"D Eskandari","year":"2017","unstructured":"Eskandari D, Zou D, Grote L, Schneider H, Penzel T, Hedner J (2017) Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea. Respir Res 18(1):130","journal-title":"Respir Res"},{"key":"3430_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.sleep.2022.11.041","volume":"102","author":"D Zou","year":"2023","unstructured":"Zou D, Grote L, Basoglu OK, Verbraecken J, Schiza S, Sliwinski P et al (2023) Arterial bicarbonate is associated with hypoxic burden and uncontrolled hypertension in obstructive sleep apnea - The ESADA cohort. Sleep Med 102:39\u201345","journal-title":"Sleep Med"},{"key":"3430_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"issue":"4","key":"3430_CR17","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1101\/pdb.prot102269","volume":"2020","author":"CL Kielkopf","year":"2020","unstructured":"Kielkopf CL, Bauer W, Urbatsch IL (2020) Bradford assay for determining protein concentration. Cold Spring Harb Protoc 2020(4):102269","journal-title":"Cold Spring Harb Protoc"},{"key":"3430_CR18","volume-title":"The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 2.4 Darien","author":"RB Berry","year":"2017","unstructured":"Berry RB, Brooks R, Gamaldo CE, Harding SM, Marcus CL, Vaughn BV (2017) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 2.4 Darien. American Academy of Sleep Medicine, Illinois"},{"issue":"4","key":"3430_CR19","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1073\/pnas.98.4.1918","volume":"98","author":"S Parkkila","year":"2001","unstructured":"Parkkila S, Parkkila AK, Rajaniemi H, Shah GN, Grubb JH, Waheed A et al (2001) Expression of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human brain. Proc Natl Acad Sci U S A 98(4):1918\u20131923","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3430_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2174\/138161208783877947","volume":"14","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 14(7):641\u2013648","journal-title":"Curr Pharm Des"},{"issue":"1","key":"3430_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1183\/09031936.00158413","volume":"44","author":"D Eskandari","year":"2014","unstructured":"Eskandari D, Zou D, Karimi M, Stenlof K, Grote L, Hedner J (2014) Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. Eur Respir J 44(1):140\u2013149","journal-title":"Eur Respir J"},{"issue":"5","key":"3430_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.amjms.2020.12.022","volume":"361","author":"D Gao","year":"2021","unstructured":"Gao D, Wang Y, Zhang R, Zhang Y (2021) Efficacy of Acetazolamide for the prophylaxis of acute mountain sickness: A systematic review, Meta-Analysis and trial sequential analysis of randomized clinical trials. Am J Med Sci 361(5):635\u2013645","journal-title":"Am J Med Sci"},{"key":"3430_CR23","unstructured":"Stenkilsson Hoff E (2023) Pharmacological therapy in obstructive sleep apnea: Methodology and interventional aspects of carbonic anhydrase modulation [Doctoral thesis]. Gothenburg: University of Gothenburg"},{"issue":"7","key":"3430_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/thorax-2023-220037","volume":"78","author":"CD Turnbull","year":"2023","unstructured":"Turnbull CD, Stradling JR (2023) Endotyping, phenotyping and personalised therapy in obstructive sleep apnoea: are we there yet? Thorax 78(7):726\u2013732","journal-title":"Thorax"},{"key":"3430_CR25","doi-asserted-by":"crossref","unstructured":"Finnsson E, Arnard\u00f3ttir E, Cheng W-J, Alex RM, Sigmarsd\u00f3ttir \u00deB, Helgason S et al (2023) Sleep apnea endotypes: from the physiological laboratory to scalable polysomnographic measures. Front Sleep.;2","DOI":"10.3389\/frsle.2023.1188052"},{"key":"3430_CR26","doi-asserted-by":"publisher","first-page":"1239016","DOI":"10.3389\/fneur.2023.1239016","volume":"14","author":"WT McNicholas","year":"2023","unstructured":"McNicholas WT, Korkalainen H (2023) Translation of obstructive sleep apnea pathophysiology and phenotypes to personalized treatment: a narrative review. Front Neurol 14:1239016","journal-title":"Front Neurol"},{"key":"3430_CR27","doi-asserted-by":"crossref","unstructured":"Geckil AA, Kiran TR, Berber NK, Otlu O, Erdem M, In E (2022) Carbonic anhydrase IX as a marker of disease severity in obstructive sleep apnea. Med (Kaunas).;58(11)","DOI":"10.3390\/medicina58111643"},{"issue":"3","key":"3430_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jsmc.2022.06.010","volume":"17","author":"J Hedner","year":"2022","unstructured":"Hedner J, Zou D (2022) Turning over a new Leaf-Pharmacologic therapy in obstructive sleep apnea. Sleep Med Clin 17(3):453\u2013469","journal-title":"Sleep Med Clin"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-025-03430-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:12:43Z","timestamp":1761127963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-025-03430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s11325-025-03430-z","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol used for the completion of the current study were approved by a local independent Institutional review board (R409-97 and R268-98, Dnr 2019\u201305096 and Dnr 04\u201318) and conducted in accordance with the declaration of Helsinki and local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and patient consent"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"AMK, SM, and DZ declare no conflict of interest. LG reports speaker\u2019s bureau for ResMed Inc., Philips, Lundbeck and Astra Zeneca outside the scope of the current work. JH participated in the DSMB for Respicardia. LG and JH received unrestricted grants on behalf of the ESADA group from ResMed Inc and Philips Respironics, research grants from Bayer Pharma and Desitin GmbH. LG, KS and JH are previous part owners of two patents related to sleep apnea therapy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"278"}}